<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
<head>
<meta http-equiv="Content-Type" content=
"text/html; charset=utf-8" /><!-- AppResources meta begin -->

<script type="text/javascript">
//<![CDATA[
var ncbi_startTime = new Date();
//]]>
</script><!-- AppResources meta end -->
<!-- TemplateResources meta begin -->
<meta name="paf_template" content="" />
<!-- TemplateResources meta end -->
<!-- Logger begin -->
<meta name="ncbi_db" content="pmc" />
<meta name="ncbi_pdid" content="article" />
<meta name="ncbi_acc" content="" />
<meta name="ncbi_domain" content="brjclinpharm" />
<meta name="ncbi_report" content="record" />
<meta name="ncbi_type" content="fulltext" />
<meta name="ncbi_objectid" content="" />
<meta name="ncbi_pcid" content="/articles/PMC2015011/" />
<meta name="ncbi_app" content="pmc" /><!-- Logger end -->
<title>Identification of the human cytochrome P450 isoforms
mediating in vitro N-dealkylation of perphenazine</title>
<!-- AppResources external_resources begin -->
<link rel="stylesheet" href="/core/jig/1.14.4/css/jig.min.css" />
<script type="text/javascript" src=
"/core/jig/1.14.4/js/jig.min.js">
</script><!-- AppResources external_resources end -->
<!-- Page meta begin -->
<meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE" />
<link rel="canonical" href="/pmc/articles/PMC2015011/" />
<link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" />
<meta name="citation_journal_title" content=
"British Journal of Clinical Pharmacology" />
<meta name="citation_title" content=
"Identification of the human cytochrome P450 isoforms mediating in vitro N-dealkylation of perphenazine" />
<meta name="citation_authors" content=
"Ole V Olesen, Kristian Linnet" />
<meta name="citation_date" content="December 2000" />
<meta name="citation_issue" content="6" />
<meta name="citation_volume" content="50" />
<meta name="citation_firstpage" content="563" />
<meta name="citation_doi" content=
"10.1046/j.1365-2125.2000.00298.x" />
<meta name="citation_abstract_html_url" content=
"/pmc/articles/PMC2015011/?report=abstract" />
<meta name="citation_pmid" content="11136295" />
<meta name="DC.Title" content=
"Identification of the human cytochrome P450 isoforms mediating in vitro N-dealkylation of perphenazine" />
<meta name="DC.Type" content="Text" />
<meta name="DC.Publisher" content="Wiley-Blackwell" />
<meta name="DC.Contributor" content="Ole V Olesen" />
<meta name="DC.Contributor" content="Kristian Linnet" />
<meta name="DC.Date" content="2000 Dec" />
<meta name="DC.Identifier" content=
"10.1046/j.1365-2125.2000.00298.x" />
<meta name="DC.Language" content="en" />
<meta property="og:title" content=
"Identification of the human cytochrome P450 isoforms mediating in vitro N-dealkylation of perphenazine" />
<meta property="og:type" content="article" />
<meta property="og:description" content=
"To identify the human cytochrome P450 (CYP) isoforms mediating the N-dealkylation of the antipsychotic drug perphenazine in vitro and estimate the relative contributions of the CYP isoforms involved.cDNA-expressed CYP isoforms were used to identify the ..." />
<meta property="og:url" content=
"http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2015011/" />
<meta property="og:site_name" content="PubMed Central (PMC)" />
<meta property="og:image" content=
"http://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/pmc-logo-share.png" />
<meta name="twitter:card" content="summary" />
<meta name="twitter:site" content="@ncbi" />
<link rel="stylesheet" href="/corehtml/pmc/css/3.4/pmc.min.css"
type="text/css" />
<link rel="stylesheet" href=
"/corehtml/pmc/css/3.4/pmc_extras_prnt.min.css" type="text/css"
media="print" />
<script type="text/javascript" src=
"/corehtml/pmc/js/common.min.js">
//<![CDATA[
//
//]]>
</script>
<script type="text/javascript" src=
"/corehtml/pmc/js/NcbiTagServer.min.js">
//<![CDATA[
//
//]]>
</script>
<meta name="citationexporter" content=
"backend:'/pmc/utils/ctxp/'" />
<script type="text/javascript" src=
"/corehtml/pmc/ctxp/jquery.citationexporter.js">
//<![CDATA[
//
//]]>
</script>
<link rel="stylesheet" href=
"/corehtml/pmc/ctxp/citationexporter.css" type="text/css" />
<script type="text/javascript" src=
"/core/mathjax/2.6.1/MathJax.js?config=/corehtml/pmc/js/mathjax-config-classic.3.4.js">
</script>
<script type="text/javascript" src=
"/corehtml/pmc/js/large-obj-scrollbars.min.js">
</script>
<script type="text/javascript">
//<![CDATA[
window.name="mainwindow";
//]]>
</script>
<style type="text/css">
/*<![CDATA[*/
.pmc-wm {background:transparent repeat-y top left;background-image:url(/corehtml/pmc/pmcgifs/wm-brjclinpharm.gif);background-size: auto, contain}
/*]]>*/
</style>

<style type="text/css">
/*<![CDATA[*/
.print-view{display:block}
/*]]>*/
</style>

<style type="text/css">
/*<![CDATA[*/
        div.pmc_para_cit li.highlight,
        div.pmc_para_cit li.highlight .one_line_source
        { background: #E0E0E0; }
        a.bibr.highlight { background: #E0E0E0; } 
/*]]>*/
</style>
<link rel="alternate" type="application/epub+zip" href=
"/pmc/articles/PMC2015011/epub/" />
<link rel="alternate" type="application/pdf" href=
"/pmc/articles/PMC2015011/pdf/bcp0050-0563.pdf" />
<!-- Page meta end -->
<link rel="shortcut icon" href=
"//www.ncbi.nlm.nih.gov/favicon.ico" />
<meta name="ncbi_phid" content=
"F4FC46756FE7C5C10000000000C8E4B5" />
<link type="text/css" rel="stylesheet" href=
"//static.pubmed.gov/portal/portal3rc.fcgi/4072591/css/3852956/3985586/3808861/3734262/3974050/3917732/251717/4048120/3846471/14534/45193/3988413/3849091/3984811/3751656/4033350/3840896/3577051/3852958/3881636/3579733/4062871/12930/3964959/3855473/4047625/3854974/3854955/4076335/4052581/9685/3549676/3609192/3609193/3609213/3395586/3855312.css" />
<link type="text/css" rel="stylesheet" href=
"//static.pubmed.gov/portal/portal3rc.fcgi/4072591/css/3411343/3882866/3929378.css"
media="print" />
</head>
<body class="article">
<div class="grid">
<div class="col twelve_col nomargin shadow">
<!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
<div class="sysmessages"><noscript>
<p class="nojs"><strong>Warning:</strong> The NCBI web site
requires JavaScript to function. <a href=
"/guide/browsers/#enablejs" title="Learn how to enable JavaScript"
target="_blank">more...</a></p>
</noscript></div>
<!--/.sysmessage-->
<div class="wrap">
<div class="page">
<div class="top">
<div class="universal_header" id="universal_header">
<ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id=
"navcontent">
<li class=
"ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt">
<a class="ui-ncbimenu-link-first" href="/" role="banner" title=
"NCBI Home" id="ncbihome" accesskey="1"><span class=
"offscreen_noflow">NCBI</span><img src=
"//static.pubmed.gov/portal/portal3rc.fcgi/4072591/img/28977"
class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li>
<li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href=
"#maincontent" title="Skip to the content" tabindex="0" accesskey=
"3">Skip to main content</a></li>
<li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href=
"#navcontent" title="Skip to the navigation" tabindex="0"
accesskey="4">Skip to navigation</a></li>
<li id="resource-menu" class=
"topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset">
<a class=
"ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown"
href=
"/static/header_footer_ajax/submenu/#resources">Resources</a></li>
<li id="all-howtos-menu" class=
"topmenu ui-helper-reset ui-ncbimenu-item-first"><a class=
"ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown"
href="/static/header_footer_ajax/submenu/#howto">How To</a></li>
<li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href=
"/guide/browsers/#accesskeys" title="About My NCBI Accesskeys"
tabindex="0" accesskey="0">About NCBI Accesskeys</a></li>
</ul>
<div class="myncbi"><span id="myncbiusername" style=
"display:none"><a href="/account/settings/" id="mnu" title=
"Edit account settings"></a></span><a accesskey="2" href="/myncbi/"
id="myncbi" style="display:none">My NCBI</a><a href="/account/" id=
"sign_in">Sign in to NCBI</a><a href="/account/signout/" id=
"sign_out" style="display:none">Sign Out</a></div>
</div>
<div class="header">
<div class="res_logo">
<h1 class="img_logo"><a href="/pmc/" class=
"pmc_logo offscreen">PMC</a></h1>
<div class="NLMLogo"><a href="http://www.nlm.nih.gov/" title=
"US National Library of Medicine">US National Library of
Medicine</a><br />
<a href="http://www.nih.gov/" title=
"National Institutes of Health">National Institutes of
Health</a></div>
</div>
<div class="search">
<form method="get" action="/pmc/">
<div class="search_form"><label for="database" class=
"offscreen_noflow">Search database</label><select id="database">
<optgroup label="Recent">
<option value="pmc" selected="selected" class="last" data-ac_dict=
"pmc-search-autocomplete">PMC</option>
</optgroup>
<optgroup label="All">
<option value="gquery">All Databases</option>
<option value="assembly">Assembly</option>
<option value="bioproject">BioProject</option>
<option value="biosample">BioSample</option>
<option value="biosystems">BioSystems</option>
<option value="books">Books</option>
<option value="clinvar">ClinVar</option>
<option value="clone">Clone</option>
<option value="cdd">Conserved Domains</option>
<option value="gap">dbGaP</option>
<option value="dbvar">dbVar</option>
<option value="epigenomics">Epigenomics</option>
<option value="nucest">EST</option>
<option value="gene">Gene</option>
<option value="genome">Genome</option>
<option value="gds">GEO DataSets</option>
<option value="geoprofiles">GEO Profiles</option>
<option value="nucgss">GSS</option>
<option value="gtr">GTR</option>
<option value="homologene">HomoloGene</option>
<option value="medgen">MedGen</option>
<option value="mesh">MeSH</option>
<option value="ncbisearch">NCBI Web Site</option>
<option value="nlmcatalog">NLM Catalog</option>
<option value="nuccore">Nucleotide</option>
<option value="omim">OMIM</option>
<option value="pmc" data-ac_dict="pmc-search-autocomplete">
PMC</option>
<option value="popset">PopSet</option>
<option value="probe">Probe</option>
<option value="protein">Protein</option>
<option value="proteinclusters">Protein Clusters</option>
<option value="pcassay">PubChem BioAssay</option>
<option value="pccompound">PubChem Compound</option>
<option value="pcsubstance">PubChem Substance</option>
<option value="pubmed">PubMed</option>
<option value="pubmedhealth">PubMed Health</option>
<option value="snp">SNP</option>
<option value="sra">SRA</option>
<option value="structure">Structure</option>
<option value="taxonomy">Taxonomy</option>
<option value="toolkit">ToolKit</option>
<option value="toolkitall">ToolKitAll</option>
<option value="toolkitbook">ToolKitBook</option>
<option value="toolkitbookgh">ToolKitBookgh</option>
<option value="unigene">UniGene</option>
</optgroup>
</select>
<div class="nowrap"><label for="term" class="offscreen_noflow"
accesskey="/">Search term</label>
<div class="nowrap"><input type="text" name="term" id="term" title=
"Search PMC. Use up and down arrows to choose an item from the autocomplete."
value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" config=
"dictionary:'pmc-search-autocomplete',disableUrl:'NcbiSearchBarAutoComplCtrl'"
autocomplete="off" data-sbconfig=
"ds:'no',pjs:'no',afs:'yes'" /></div>
<button id="search" type="submit" class="button_search nowrap" cmd=
"go">Search</button></div>
</div>
</form>
<ul class="searchlinks inline_list">
<li><a href="/pmc/limits/">Limits</a></li>
<li><a href="/pmc/advanced/">Advanced</a></li>
<li><a href="/pmc/journals/">Journal list</a></li>
<li class="help"><a target="_blank" href=
"/books/NBK3825/">Help</a></li>
</ul>
</div>
</div>
<!--<component id="Page" label="headcontent"/>--></div>
<div class="content"><!-- site messages -->
<div class="container">
<div id="maincontent" class="content eight_col col">
<div class="navlink-box">
<ul class="page-breadcrumbs inline_list small">
<li class="journal-list"><a href="/pmc/journals/" class=
"navlink">Journal List</a></li>
<li class="archive-page"><a class="navlink" href=
"/pmc/journals/279/">Br J Clin Pharmacol</a></li>
<li class="issue-page"><a class="navlink" href=
"/pmc/issues/151583/">v.50(6); 2000 Dec</a></li>
<li class="accid">PMC2015011</li>
</ul>
</div>
<!-- Journal banner -->
<div class="pmc-page-banner whole_rhythm">
<div><img src="/corehtml/pmc/pmcgifs/logo-brjclinpharm.gif" alt=
"Logo of brjclinpharm" usemap="#logo-imagemap" /><map id=
"logo-imagemap" name="logo-imagemap">
<area alt="Link to Publisher's site" title=
"Link to Publisher's site" shape="default" coords="0,0,499,74"
href="http://www.blackwellpublishing.com/journal.asp?ref=0306-5251"
target="pmc_ext" ref=
"reftype=publisher&amp;article-id=2015011&amp;issue-id=151583&amp;journal-id=279&amp;FROM=Article%7CBanner&amp;TO=Publisher%7COther%7CN/A&amp;rendering-type=normal" />
</map></div>
</div>
<!--component id='MainPortlet' label='search-reference'/-->
<!-- Book content -->
<div class="">
<div class=
"hide-overflow article lit-style content pmc-wm slang-all page-box">
<!--main-content-->
<div class="jig-ncbiinpagenav" data-jigconfig=
"smoothScroll: false, allHeadingLevels: ['h2'], headingExclude: ':hidden'">
<div class="fm-sec half_rhythm no_top_margin">
<div class="fm-citation half_rhythm no_top_margin clearfix">
<div class="small">
<div class="inline_block eight_col va_top">
<div>
<div><span class="cit">Br J Clin Pharmacol. 2000 Dec; 50(6):
563–571.</span></div>
<div><span class="doi">doi:&nbsp; <a href=
"http://dx.doi.org/10.1046%2Fj.1365-2125.2000.00298.x" target=
"pmc_ext" ref=
"reftype=other&amp;article-id=2015011&amp;issue-id=151583&amp;journal-id=279&amp;FROM=Article%7CFront%20Matter&amp;TO=Content%20Provider%7CCrosslink%7CDOI&amp;rendering-type=normal">
10.1046/j.1365-2125.2000.00298.x</a></span></div>
</div>
</div>
<div class=
"inline_block four_col va_top show-overflow align_right">
<div class="fm-citation-ids">
<div class="fm-citation-pmcid"><span class=
"fm-citation-ids-label">PMCID:</span> <span>PMC2015011</span></div>
</div>
</div>
</div>
</div>
<h1 class="content-title">Identification of the human cytochrome
P450 isoforms mediating <em>in vitro</em> <em>N</em>-dealkylation
of perphenazine</h1>
<div class="half_rhythm">
<div class="contrib-group fm-author"><a href=
"/pubmed/?term=Olesen%20OV%5Bauth%5D">Ole V Olesen</a> and <a href=
"/pubmed/?term=Linnet%20K%5Bauth%5D">Kristian Linnet</a></div>
</div>
<div class="fm-panel small half_rhythm">
<div class="fm-authors-info fm-panel hide half_rhythm" id=
"id843688_ai" style="display:none">
<div class="fm-affl" lang="en">Institute for Basic Psychiatric
Research, Department of Biological Psychiatry, Psychiatric
University Hospital, Skovagervej 2, DK-8240 Risskov, Denmark</div>
<div id="cor1"><em>Correspondence:</em> Ole V. Olesen, Ph.Sci.,
Institute for Basic Psychiatric Research, Department of Biological
Psychiatry, Psychiatric University Hospital, Skovagervej 2, DK-8240
Risskov, Denmark. Tel: + 45 77893522; Fax: + 45 77893549; E-mail:
<a href="mailto:dev@null" data-email="kd.elet.3tsop@7091loiv"
class="oemail">kd.elet.3tsop@7091loiv</a></div>
</div>
<div class="togglers"><a href="#" class="pmctoggle" rid=
"id843688_ai">Author information <span>►</span></a> <a href="#"
class="pmctoggle" rid="id843688_an">Article notes
<span>►</span></a> <a href="#" class="pmctoggle" rid=
"id843688_cpl">Copyright and License information
<span>►</span></a></div>
<div class="fm-article-notes fm-panel hide half_rhythm" id=
"id843688_an" style="display:none">
<div class="fm-pubdate half_rhythm">Received 1999 Sep 15; Accepted
2000 Sep 7.</div>
</div>
<div class="fm-cpl-info fm-panel hide half_rhythm" id=
"id843688_cpl" style="display:none">
<div class="fm-copyright half_rhythm"><a href=
"/pmc/about/copyright.html">Copyright</a> © 2000 Blackwell Science
Ltd</div>
</div>
</div>
<div class="links-box fm-panel whole_rhythm">
<div class="small">
<div>This article has been <a href=
"/pmc/articles/PMC2015011/citedby/">cited by</a> other articles in
PMC.</div>
</div>
</div>
</div>
<div class="sec"></div>
<div id="__abstractid191476" lang="en" class="tsec sec">
<h2 class="head no_bottom_margin" id="__abstractid191476title">
Abstract</h2>
<!--article-meta-->
<div>
<div id="__sec1" class="sec sec-first">
<h3>Aims</h3>
<p id="__p1" class="p p-first-last">To identify the human
cytochrome P450 (CYP) isoforms mediating the
<em>N</em>-dealkylation of the antipsychotic drug perphenazine
<em>in vitro</em> and estimate the relative contributions of the
CYP isoforms involved.</p>
</div>
<div id="__sec2" class="sec">
<h3>Methods</h3>
<p id="__p2" class="p p-first-last">cDNA-expressed CYP isoforms
were used to identify the isoforms that are able to mediate the
<em>N</em>-dealkylation of perphenazine, which is considered a
major metabolic pathway for the drug. Using human liver microsomal
preparations (HLM), inhibition studies were carried out to
establish the relative contributions of the CYP isoforms involved
in the <em>N</em>-dealkylation reaction.</p>
</div>
<div id="__sec3" class="sec">
<h3>Results</h3>
<p id="__p3" class="p p-first-last">CYP isoforms 1A2, 3A4, 2C8,
2C9, 2C18, 2C19 and 2D6 were able to mediate the
<em>N</em>-dealkylation of perphenazine. Reaction velocities and
their relative abundance in HLM suggested that CYP1A2, 3A4, 2C19
and 2D6 were the most important contributors to
<em>N</em>-dealkylation. Apparent <em>K<sub>m</sub></em> values of
CYP1A2 and CYP2D6 were in the range 1–2 μ<span class=
"small-caps">m</span> and <em>K<sub>m</sub></em> values of CYP2C19
and CYP3A4 were 14 μ<span class="small-caps">m</span> and 7.9
μ<span class="small-caps">m</span>, respectively. Ketoconazole
inhibition of <em>N</em>-dealkylation mediated by a mixed HLM
indicated that CYP3A4 accounted for about 40% of perphenazine
<em>N</em>-dealkylation at therapeutically relevant concentrations.
The contribution of the CYP isoforms 1A2, 2C19 and 2D6 amounted to
20–25% each as measured by the percentage inhibition obtained by
addition of furafylline, fluvoxamine or quinidine, respectively.
HLM-mediated <em>N</em>-dealkylation of perphenazine accounted for
57% of the total amount of substrate consumed during
incubation.</p>
</div>
<div id="__sec4" class="sec sec-last">
<h3>Conclusions</h3>
<p id="__p4" class="p p-first-last">The present <em>in vitro</em>
study suggests that CYP isoforms 1A2, 3A4, 2C19 and 2CD6 are
primarily involved in the <em>N</em>-dealkylation of perphenazine.
The relatively modest role of CYP2D6 is at variance with <em>in
vivo</em> studies, which indicate a greater contribution of this
isoform. Alternative metabolic pathways, corresponding to 43% of
the HLM-mediated metabolism of the drug, may depend more strongly
on CYP2D6.</p>
</div>
</div>
<div class="sec"><strong class="kwd-title">Keywords:</strong>
<span class="kwd-text">cytochrome P450, human liver microsomes,
<em>N</em>-dealkylation, perphenazine</span></div>
</div>
<div id="__sec5" class="tsec sec">
<h2 class="head no_bottom_margin" id="__sec5title">
Introduction</h2>
<p id="__p5" class="p p-first">Perphenazine is a phenothiazine
derivative, which was developed in the years following the
introduction of chlorpromazine as an antipsychotic drug in 1952.
The metabolism and urinary excretion of perphenazine have been
studied both in rats and man, and measurements of the concentration
of perphenazine in serum are used for therapeutic drug monitoring
(TDM) [<a href="#b1" rid="b1" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_137064711">1</a>–<a href="#b7" rid="b7" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_137064734">7</a>]. The major steps in the metabolism of
perphenazine in humans are <em>N</em>-dealkylation leading to loss
of the hydroxyethyl group, oxidation of the sulphur atom and ring
hydroxylation at position 7 (<a href=
"/pmc/articles/PMC2015011/figure/fig01/" target="figure" class=
"fig-table-link fig figpopup" rid-figpopup="fig01" rid-ob=
"ob-fig01" co-legend-rid="lgnd_fig01"><span>Figure 1</span></a>).
Minor metabolic pathways may be N-oxidation and direct
glucuronidation of the primary alcohol group [<a href="#b3" rid=
"b3" class=" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_308640027">3</a>, <a href="#b8" rid="b8" class=
" bibr popnode">8</a>]. Receptor binding studies indicate that
7-OH-perphenazine has about 70% of the antipsychotic activity of
the parent compound, while the other metabolites are considered to
be inactive [<a href="#b9" rid="b9" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_137064730">9</a>]. Determination of perphenazine and
metabolites in serum from patients at steady-state have shown
concentrations of <em>N</em>-dealkylated perphenazine corresponding
to three times those of perphenazine, whereas perphenazine
sulphoxide concentrations were in the same range as those of the
parent compound [<a href="#b10" rid="b10" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_137064717">10</a>]. No information about the concentration
of 7-OH-perphenazine in serum is available, but this compound is
excreted in the urine mainly as the glucuronide [<a href="#b3" rid=
"b3" class=" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_308640029">3</a>, <a href="#b8" rid="b8" class=
" bibr popnode">8</a>]. <em>N</em>-dealkylated perphenazine is
eliminated as its sulphoxide, whereas about 13% of a dose is
excreted in the urine as perphenazine-sulphoxide [<a href="#b4"
rid="b4" class=" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_308640028">4</a>].</p>
<!--fig ft0--><!--fig mode=article f1-->
<div class="fig iconblock ten_col whole_rhythm clearfix" id="fig01"
co-legend-rid="lgnd_fig01"><a class="icnblk_img figpopup" href=
"/pmc/articles/PMC2015011/figure/fig01/" target="figure"
rid-figpopup="fig01" rid-ob="ob-fig01"><img src=
"/pmc/articles/PMC2015011/bin/bcp0050-0563-f1.gif" class=
"small-thumb" alt="Figure 1" title="Figure 1" src-large=
"/pmc/articles/PMC2015011/bin/bcp0050-0563-f1.jpg" /></a>
<div class="icnblk_cntnt" id="lgnd_fig01">
<div><a class="figpopup" href=
"/pmc/articles/PMC2015011/figure/fig01/" target="figure"
rid-figpopup="fig01" rid-ob="ob-fig01">Figure 1</a></div>
<!--caption a4-->
<div><span>The major routes of perphenazine
metabolism.</span></div>
</div>
</div>
<p id="__p7">The cytochrome P450 (CYP) isoforms involved in the
metabolism of perphenazine have not been studied systematically,
but indirect evidence points towards a role for CYP2D6.
Perphenazine acts as an inhibitor of the conversion of
nortriptyline to <em>(E)</em>-10-hydroxy-nortripty-line, a process
almost exclusively mediated by CYP2D6 at therapeutic nortriptyline
concentrations, and this may lead to a clinically significant
increase of the plasma nortriptyline concentration in patients
treated with both drugs [<a href="#b11" rid="b11" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_137064712">11</a>–<a href="#b13" rid="b13" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_137064718">13</a>]. Serum perphenazine concentration is
increased by addition of the selective serotonin reuptake inhibitor
(SSRI) paroxetine, which is known as a potent inhibitor of CYP2D6
[<a href="#b14" rid="b14" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_137064737">14</a>]. Finally, higher serum levels of
perphenazine corrected for dose have been found in patients lacking
CYP2D6 (poor metabolizers) than in patients having a functional
enzyme (extensive metabolizers) [<a href="#b15" rid="b15" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_137064723">15</a>, <a href="#b16" rid="b16" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_137064739">16</a>]. Other CYP isoforms, however, are also
likely to contribute to the metabolism of perphenazine. Thus, a
considerable interindividual variation of the concentration to dose
ratio (C/D) at steady-state has been found in both CYP2D6 extensive
and poor metabolizers leading to a considerable overlap of this
ratio in the two groups [<a href="#b16" rid="b16" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_137064720">16</a>]. This pattern together with the finding
that the median C/D was only increased by 100% in poor metabolizers
points towards the involvement of additional enzymes.</p>
<p id="__p8" class="p p-last">In the present <em>in vitro</em>
study the human CYP isoforms mediating the <em>N</em>-dealkylation
of perphenazine were identified. In human liver microsomal
preparations (HLM), the relative individual contributions of the
CYP isoforms involved in the <em>N</em>-dealkylation of
perphenazine were determined by defining the effect of selective
inhibitors on the formation of <em>N</em>-dealkylated perphenazine.
The relative importance of <em>N</em>-dealkylation to the total
metabolism of perphenazine by HLM was also assessed.</p>
</div>
<div id="__sec6" class="tsec sec">
<h2 class="head no_bottom_margin" id="__sec6title">Methods</h2>
<div id="__sec7" class="sec sec-first">
<h3>Chemicals and reagents</h3>
<p id="__p9" class="p p-first"><em>N</em>-dealkylated perphenazine
was a gift from Schering-Plough Research Institute (Kenilworth,
NJ). Fluvoxa-mine, ketoconazole and
(<em>E</em>)-10-hydroxy-nortriptyline (used as internal standard)
were donated by Solvay Duphar B.V. (Weesp, the Netherlands),
Janssen Pharma-ceutica N.V. (Beerse, Belgium) and Lundbeck A/S
(Copenhagen, Denmark), respectively. Quinidine and perphenazine
were from Sigma Chemical Co. (St Louis, MO), and furafylline was
obtained from Ultrafine Chemicals (Manchester, UK). Other chemicals
were of analytical grade. cDNA-expressed human CYPs 1A2, 3A4, 2C8,
2C9, 2C18, 2C19, 2E1 and 2D6, prepared from baculovirus infected
insect cells, were purchased from Gentest Co. (Woburn, MA). Human
liver microsomal preparations (HLMs) were also obtained from
Gentest Co. According to the supplier, all donors were Caucasians,
and the specimens were obtained <em>post mortem.</em> One HLM
(H161Pool, Lot 6) was a pool prepared as a mixture of microsomes
from 10 different donors. Gender was equally represented in this
pool. Three other HLMs (HG23, HG30 and HG112) were from individual
donors. The concentrations of the individual CYP isoforms in the
HLMs have been determined by Western blotting by the supplier
(<a href="/pmc/articles/PMC2015011/table/tbl1/" target="true"
class="fig-table-link table figpopup" rid-figpopup="tbl1" rid-ob=
"ob-tbl1" co-legend-rid=""><span>Table 1</span></a>). With regard
to the CYP2C family, only the content of CYP2C9 was determined. The
microsomal preparations were received frozen and were stored at
−80°C until use.</p>
<!--table ft1--><!--table-wrap mode=article t1-->
<div class="table-wrap iconblock ten_col whole_rhythm clearfix" id=
"tbl1"><a href="/pmc/articles/PMC2015011/table/tbl1/" target=
"table" rid-ob="ob-tbl1" rid-figpopup="tbl1" class=
"table img_link icnblk_img figpopup"><img alt="Table 1" title=
"Table 1" class="small-thumb" src=
"/pmc/articles/PMC2015011/table/tbl1/?report=thumb" src-large=
"/pmc/articles/PMC2015011/table/tbl1/?report=previmg" /></a>
<div class="icnblk_cntnt">
<div><a class="figpopup" href=
"/pmc/articles/PMC2015011/table/tbl1/" target="table" rid-figpopup=
"tbl1" rid-ob="ob-tbl1">Table 1</a></div>
<!--caption a4-->
<div><span>The CYP isoform content (pmol nig protein) of the pooled
and the individual human liver microsomal preparations as
determined by Western blotting using cDNA-expressed enzymes as
standards (according to Gentest Co).</span></div>
</div>
</div>
</div>
<div id="__sec8" class="sec">
<h3>Experimental procedure</h3>
<p id="__p13" class="p p-first-last">The enzymatic reactions were
carried out at pH 7.4 in propylene tubes at 37°C in a total volume
of 300 μl of 100 m<span class="small-caps">m</span> phosphate
buffer as described previously [<a href="#b17" rid="b17" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_137064733">17</a>]. The NADPH generating system consisted of
1 U isocitrate dehydrogenase, 5 m<span class="small-caps">m</span>
NADP, 5 m<span class="small-caps">m</span> isocitrate and 5
m<span class="small-caps">m</span> MgCl<sub>2</sub>. The reaction
was started by addition of 50–200 fig HLM protein or 2.5–10 pmol of
the individual CYP isoforms and stopped 10 min later by addition of
1 ml ice-cold 1 <span class="small-caps">m</span>
carbonate/bicarbonate buffer, pH 10.5. Control values were obtained
at all substrate concentrations by adding the stop reagent before
the microsomes. In order to assess the CYP isoforms involved in the
<em>N</em>-dealkylation of perphenazine and to study the linearity
of <em>N</em>-dealkylated perphenazine formation, incubation times
up to 60 min were used for substrate concentrations of 2, 10 and
100 μ<span class="small-caps">m</span>. For all processes
proportionality was found between the amount of enzyme added and
the product formed, and <em>N</em>-dealkylated perphenazine
formation was linear up to about 12 min of incubation.</p>
</div>
<div id="__sec9" class="sec">
<h3>Inhibitor studies</h3>
<p id="__p14" class="p p-first-last">Chemical inhibitors were added
to the reaction medium in order to determine the quantitative
contribution of the individual CYP isoforms to the formation of
total <em>N</em>-dealkylated perphenazine in HLM. Furafylline,
ketoco-nazole, fluvoxamine and quinidine were used as inhibitors of
CYP1A2, 3A4, 2C19 and 2D6, respectively [<a href="#b18" rid="b18"
class=" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_137064729">18</a>–<a href="#b23" rid="b23" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_137064724">23</a>]. Furafylline was used as a competitive
inhibitor in the present study (23). This inhibitor is almost
insoluble in water but soluble in dimethyl sulphoxide (DMSO). A
final concentration of 1% DMSO was used in both the control
(uninhibited) reaction medium and the medium containing the
inhibitor. The specificity of CYP inhibitors is usually only
relative and depends on the concentration of an inhibitor. The
activity of several CYP isoforms may be inhibited to various
extents by an individual inhibitor [<a href="#b22" rid="b22" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_137064710">22</a>]. Furthermore, given a competitive
mechanism of inhibition, the extent of inhibition of the reaction
rate depends on the substrate concentration,
<em>K<sub>m</sub></em>, concentration of the inhibitor and the
affinity of the inhibitor <em>K</em><sub>i</sub> [<a href="#b24"
rid="b24" class=" bibr popnode">24</a>]. Thus, initial inhibition
experiments were carried out to determine suitable inhibitor
concentrations in the present context.</p>
</div>
<div id="__sec10" class="sec">
<h3>Assay of perphenazine and dealkylated perphenazine</h3>
<p id="__p15" class="p p-first-last">The <em>N</em>-dealkylated
perphenazine formed during the incubation period was determined by
h.p.l.c. essentially as described previously for the determination
of citalopram metabolites [<a href="#b25" rid="b25" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_137064728">25</a>]. After addition of 50 μl 3 μ<span class=
"small-caps">m</span> <em>(E)</em>-l0-OH-nortriptyline as internal
standard, <em>N</em>-dealkylated perphenazine in the incubate was
extracted into 7.5 ml heptane-isoamylalcohol (97.5 :1.5; v/v) by
shaking. After centrifugation the aqueous phase was frozen by
immersing the tubes in a mixture of dry ice and ethanol. The
organic phase was transferred to new tubes, and the analytes were
back-extracted into 125 μl of 250 m<span class=
"small-caps">m</span> phosphoric acid, of which 75 μl was injected
onto a h.p.l.c. instrument equipped with a Hypersil BDS
C<sub>18</sub> column. The mobile phase was an acetonitrile-44
m<span class="small-caps">m</span> KH<sub>2</sub>PO<sub>4</sub>
buffer, pH 2.5 (67.5 :32.5; v/v), which contained 10 m<span class=
"small-caps">m</span> triethylamine. The lower level of
quantification was 3 pmol <em>N</em>-dealkylated perphenazine. The
interday precision was &lt; 8%.</p>
</div>
<div id="__sec11" class="sec sec-last">
<h3>Analysis of data</h3>
<p id="__p16" class="p p-first-last">Reaction velocities
(<em>V</em>) were expressed as nmol h<sup>−1</sup> mg<sup>−1</sup>
protein, when HLM was used, and as nmol h<sup>−1</sup>
nmol<sup>−1</sup> CYP, when the activities of the CYP isoforms were
measured. Apparent <em>K<sub>m</sub></em> and
<em>V<sub>max</sub></em> values were calculated by nonlinear
regression analysis according to the Michae-lis-Menten equation
using GraphPad Prism software (San Diego, CA). An <em>F</em>-test
indicated whether a one-or two-binding site model was optimal. An
Eadie-Hofstee plot, <em>V vs V/S</em>, where <em>S</em> is the
substrate concentration, was used to illustrate multiple binding
sites [<a href="#b26" rid="b26" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_137064735">26</a>]. Degrees of inhibition were expressed as
a percentage of the corresponding uninhibited control reaction. A
Student's t-test was used to test for statistical significance.</p>
</div>
</div>
<div id="__sec12" class="tsec sec">
<h2 class="head no_bottom_margin" id="__sec12title">Results</h2>
<div id="__sec13" class="sec sec-first">
<h3><em>N</em>-Dealkylation of perphenazine by cDNA-expressed CYP
isoforms</h3>
<p id="__p17" class="p p-first">Initially, we screened the
cDNA-expressed CYP isoforms 1A2, 3A4, 2C8, 2C9, 2C18, 2C19, 2D6 and
2E1 for their ability to catalyse the <em>N</em>-dealkylation of
perphenazine. Only CYP2E1 did not display a measurable activity.
The reaction rate of <em>N</em>-dealkylation as a function of the
substrate concentration in the range 0–50 μM was measured, and the
calculated <em>K<sub>m</sub></em>, <em>V<sub>max</sub></em> and
CL<em><sub>int</sub></em>(<em>V<sub>max/</sub>K<sub>m</sub></em>)
values are given in <a href="/pmc/articles/PMC2015011/table/tbl2/"
target="true" class="fig-table-link table figpopup" rid-figpopup=
"tbl2" rid-ob="ob-tbl2" co-legend-rid=""><span>Table 2</span></a>.
For CYP1A2, CYP3A4 and CYP2D6 significantly better fits were
obtained, when the Michaelis-Menten equation using two binding
sites was used. The CL<em><sub>lnt</sub></em> values point towards
major contributions by CYP1A2, CYP3A4, CYP2C19 and CYP2D6, and
<a href="/pmc/articles/PMC2015011/figure/fig02/" target="figure"
class="fig-table-link fig figpopup" rid-figpopup="fig02" rid-ob=
"ob-fig02" co-legend-rid="lgnd_fig02"><span>Figure 2</span></a>
displays the relation between reaction rate (<em>V</em>) and the
ratio of reaction rate to substrate concentration (<em>V/S</em>)
for these CYP isoforms (Eadie-Hofstee plots). The shapes of the
plots for CYPs 1A2, 3A4, and 2D6 are in accordance with the
presence of more than one binding site.</p>
<!--table ft1--><!--table-wrap mode=article t1-->
<div class="table-wrap iconblock ten_col whole_rhythm clearfix" id=
"tbl2"><a href="/pmc/articles/PMC2015011/table/tbl2/" target=
"table" rid-ob="ob-tbl2" rid-figpopup="tbl2" class=
"table img_link icnblk_img figpopup"><img alt="Table 2" title=
"Table 2" class="small-thumb" src=
"/pmc/articles/PMC2015011/table/tbl2/?report=thumb" src-large=
"/pmc/articles/PMC2015011/table/tbl2/?report=previmg" /></a>
<div class="icnblk_cntnt">
<div><a class="figpopup" href=
"/pmc/articles/PMC2015011/table/tbl2/" target="table" rid-figpopup=
"tbl2" rid-ob="ob-tbl2">Table 2</a></div>
<!--caption a4-->
<div><span><em>K<sub>m</sub></em>, <em>V<sub>max</sub></em> and
CL<em><sub>int</sub></em>, (<em>V<sub>max</sub>/K<sub>m</sub></em>)
for the <em>N</em>-dealkylation of perphenazine mediated by
cDNA-expressed isoforms (mean with s.e. in parenthesis). The
parameters were calculated on the basis of duplicate incubations
using 5–9 different substrate concentrations.</span>
<strong>...</strong></div>
</div>
</div>
<!--fig ft0--><!--fig mode=article f1-->
<div class="fig iconblock ten_col whole_rhythm clearfix" id="fig02"
co-legend-rid="lgnd_fig02"><a class="icnblk_img figpopup" href=
"/pmc/articles/PMC2015011/figure/fig02/" target="figure"
rid-figpopup="fig02" rid-ob="ob-fig02"><img src=
"/pmc/articles/PMC2015011/bin/bcp0050-0563-f2.gif" class=
"small-thumb" alt="Figure 2" title="Figure 2" src-large=
"/pmc/articles/PMC2015011/bin/bcp0050-0563-f2.jpg" /></a>
<div class="icnblk_cntnt" id="lgnd_fig02">
<div><a class="figpopup" href=
"/pmc/articles/PMC2015011/figure/fig02/" target="figure"
rid-figpopup="fig02" rid-ob="ob-fig02">Figure 2</a></div>
<!--caption a4-->
<div><span>Eadie-Hofstee plots displaying rates of perphenazine
<em>N</em>-dealkylation <em>(V)</em> mediated by cDNA-expressed
CYPs 1A2, 3A4, 2C19 and 2D6 as a function of the ratio between
reaction rate and substrate concentration <em>(V/S).</em> The
substrate concentration ranges from</span>
<strong>...</strong></div>
</div>
</div>
</div>
<div id="__sec14" class="sec">
<h3>Specificity of CYP inhibitors</h3>
<p id="__p23" class="p p-first">Initial inhibition experiments were
carried out using cDNA-expressed CYP isoforms in order to determine
inhibitor concentrations characterized by a high inhibition of the
target CYP isoform and a reasonably low inhibitory effect towards
the other CYP isoforms (<a href=
"/pmc/articles/PMC2015011/figure/fig03/" target="figure" class=
"fig-table-link fig figpopup" rid-figpopup="fig03" rid-ob=
"ob-fig03" co-legend-rid="lgnd_fig03"><span>Figure 3</span></a>). A
substrate concentration of 4 μ<span class="small-caps">m</span> was
used for all inhibitor experiments. Furafylline was added to the
incubation medium in the concentration range 1.25–50 μ<span class=
"small-caps">m</span>, and the inhibitory effect on the
CYP1A2-mediated <em>N</em>-dealkylated perphenazine formation was
measured. In order to obtain more than 80% inhibition of the
control reaction, a furafylline concentration of 50 μ<span class=
"small-caps">m</span> was necessary, but concentrations exceeding
25 μ<span class="small-caps">m</span> resulted in more than 20%
inhibition of the CYP2C19-mediated reaction. No significant
inhibition of CYP2D6 or CYP3A4 activities was found, when 25
μ<span class="small-caps">m</span> furafylline was added to the
medium. Thus, this concentration, which yielded 75% inhibition of
CYP1A2, was chosen for inhibition of HLM-mediated reactions. In the
same manner, ketoco-nazole was studied in the range 0.125
μ<span class="small-caps">m</span> to 1 μ<span class=
"small-caps">m</span>, and the optimum concentration was found to
be 0.5 μ<span class="small-caps">m</span>. At this concentration,
CYP3A4 was inhibited by 98%, and the other reactions were either
insignificantly inhibited or only slightly inhibited (13% as
regards CYP2C19). For fluvoxamine, the range 0.125 μ<span class=
"small-caps">m</span> to 5 μ<span class="small-caps">m</span> was
considered with selection of 0.25 μ<span class=
"small-caps">m</span> as the optimum value. The target enzyme,
CYP2C19, was only inhibited by 52% at this concentration, but an
increase of the fluvoxamine concentration to more than 0.25
μ<span class="small-caps">m</span> resulted in a too high
inhibition of CYP1A2 and also led to significant inhibition of
CYP3A4 and CYP2D6. Finally, the inhibitory effect of quinidine was
tested over the range 0.125 μ<span class="small-caps">m</span> to
10 μ<span class="small-caps">m</span>, and 5 μ<span class=
"small-caps">m</span> was selected as the optimum concentration for
further experiments. This relatively high concentration was needed
to attain 80% inhibition of CYP2D6 activity. CYP3A4 activity was
inhibited by 16%, whereas that of the other two isoforms not were
subject to significant inhibition by 5 μ<span class=
"small-caps">m</span> quinidine.</p>
<!--fig ft0--><!--fig mode=article f1-->
<div class="fig iconblock ten_col whole_rhythm clearfix" id="fig03"
co-legend-rid="lgnd_fig03"><a class="icnblk_img figpopup" href=
"/pmc/articles/PMC2015011/figure/fig03/" target="figure"
rid-figpopup="fig03" rid-ob="ob-fig03"><img src=
"/pmc/articles/PMC2015011/bin/bcp0050-0563-f3.gif" class=
"small-thumb" alt="Figure 3" title="Figure 3" src-large=
"/pmc/articles/PMC2015011/bin/bcp0050-0563-f3.jpg" /></a>
<div class="icnblk_cntnt" id="lgnd_fig03">
<div><a class="figpopup" href=
"/pmc/articles/PMC2015011/figure/fig03/" target="figure"
rid-figpopup="fig03" rid-ob="ob-fig03">Figure 3</a></div>
<!--caption a4-->
<div><span>Inhibition of cDNA-expressed CYP isoform-mediated
JV-dealkylation of perphenazine. The substrate concentration was 4
μ<span class="small-caps">m</span>, and inhibition is expressed as
a percentage of the rate of the control reaction without
inhibitors. The bars and vertical</span> <strong>...</strong></div>
</div>
</div>
</div>
<div id="__sec15" class="sec">
<h3><em>N</em>-Dealkylation of perphenazine by human liver
microsomal preparations</h3>
<p id="__p25" class="p p-first">The rate of <em>N</em>-dealkylated
perphenazine formation at various substrate concentrations mediated
by the HLM pool is shown in <a href=
"/pmc/articles/PMC2015011/figure/fig04/" target="figure" class=
"fig-table-link fig figpopup" rid-figpopup="fig04" rid-ob=
"ob-fig04" co-legend-rid="lgnd_fig04"><span>Figure 4</span></a> in
the form of an Eadie-Hofstee plot. The shape of the plot may be
interpreted as a significant involvement of several CYP isoforms
with one exhibiting substrate inhibition.</p>
<!--fig ft0--><!--fig mode=article f1-->
<div class="fig iconblock ten_col whole_rhythm clearfix" id="fig04"
co-legend-rid="lgnd_fig04"><a class="icnblk_img figpopup" href=
"/pmc/articles/PMC2015011/figure/fig04/" target="figure"
rid-figpopup="fig04" rid-ob="ob-fig04"><img src=
"/pmc/articles/PMC2015011/bin/bcp0050-0563-f4.gif" class=
"small-thumb" alt="Figure 4" title="Figure 4" src-large=
"/pmc/articles/PMC2015011/bin/bcp0050-0563-f4.jpg" /></a>
<div class="icnblk_cntnt" id="lgnd_fig04">
<div><a class="figpopup" href=
"/pmc/articles/PMC2015011/figure/fig04/" target="figure"
rid-figpopup="fig04" rid-ob="ob-fig04">Figure 4</a></div>
<!--caption a4-->
<div><span>Perphenazine <em>N</em>-dealkylation mediated by a
pooled human liver microsomal preparation (H161Pool). The data are
presented as an Eadie-Hofstee plot showing the JV-dealkylation rate
<em>(V)</em> as a function of <em>VIS,</em> where S is the
perphenazine concentration. Each</span> <strong>...</strong></div>
</div>
</div>
<p id="__p27" class="p">The contributions of the individual CYP
isoforms to perphenazine <em>N</em>-dealkylation were assessed by
inhibition experiments using the HLM pool and the three individual
HLM preparations. The optimal inhibitor concentrations outlined
above were used. <a href="/pmc/articles/PMC2015011/figure/fig05/"
target="figure" class="fig-table-link fig figpopup" rid-figpopup=
"fig05" rid-ob="ob-fig05" co-legend-rid="lgnd_fig05"><span>Figure
5</span></a> presents the mean values for inhibition together with
the quantitative amounts of the CYP isoforms in the various HLM
preparations (see <a href="/pmc/articles/PMC2015011/table/tbl1/"
target="true" class="fig-table-link table figpopup" rid-figpopup=
"tbl1" rid-ob="ob-tbl1" co-legend-rid=""><span>Table 1</span></a>).
Of the CYP2C family only CYP2C9 was quantified, but according to
studies by other authors the mean catalytic activity of CYP2C19
amounts to about 25% of CYP2C9 activity [<a href="#b27" rid="b27"
class=" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_137064736">27</a>]. The contribution of CYP1A2 was verified
by a significant inhibition by furafylline in all but the HLM
assigned HG112, which had a very low CYP1A2 content. In the latter
HLM, only 2.6% inhibition was observed. The involvement of CYP3A4
as measured by ketoconazole inhibition varied roughly in proportion
to the CYP3A4 content of the four HLMs. In microsomes from liver
HG112 fluvoxamine but not furafylline had a significant inhibitory
effect on perphenazine metabolism, indicating the involvement of
CYP2C19. Finally, the contribution of CYP2D6 is demonstrated by
inhibition by quinidine, the extent of which was related to the
amount isoform present. In microsomes from HG30 quinidine inhibited
perphenazine <em>N</em>-dealkylation significantly by 13%, although
the preparation did not contain a measurable amount of CYP2D6. This
may be ascribed to a small degree of inhibition of CYP3A4 activity
by quinidine (see <a href="/pmc/articles/PMC2015011/figure/fig03/"
target="figure" class="fig-table-link fig figpopup" rid-figpopup=
"fig03" rid-ob="ob-fig03" co-legend-rid="lgnd_fig03"><span>Figure
3</span></a>). Assuming H161Pool microsomes represent an average
HLM, our data indicate that the mean contribution of CYP3A4 to
perphenazine <em>N</em>-dealkylation is about 40% of total
<em>N</em>-dealkylated perphenazine formed, and those of CYPs 1A2,
2C19 and 2D6 are 20–25% each. With respect to the three individual
HLMs, the contribution of CYP2D6 varied from 13% to 44% and that of
CYP3A4 from 14% to</p>
<!--fig ft0--><!--fig mode=article f1-->
<div class="fig iconblock ten_col whole_rhythm clearfix" id="fig05"
co-legend-rid="lgnd_fig05"><a class="icnblk_img figpopup" href=
"/pmc/articles/PMC2015011/figure/fig05/" target="figure"
rid-figpopup="fig05" rid-ob="ob-fig05"><img src=
"/pmc/articles/PMC2015011/bin/bcp0050-0563-f5.gif" class=
"small-thumb" alt="Figure 5" title="Figure 5" src-large=
"/pmc/articles/PMC2015011/bin/bcp0050-0563-f5.jpg" /></a>
<div class="icnblk_cntnt" id="lgnd_fig05">
<div><a class="figpopup" href=
"/pmc/articles/PMC2015011/figure/fig05/" target="figure"
rid-figpopup="fig05" rid-ob="ob-fig05">Figure 5</a></div>
<!--caption a4-->
<div><span>Effect of selective CYP inhibitors on perphenazine
<em>N</em>-dealkylation mediated by a pooled human liver microsomal
preparation (H161Pool) and three individual liver microsomal
preparations (HG23, HG30 and HG112). The substrate concentration
was 4 μ</span> <strong>...</strong></div>
</div>
</div>
</div>
<div id="__sec16" class="sec sec-last">
<h3>Substrate consumption and <em>N</em>-dealkylated
perphenazine</h3>
<p id="__p29" class="p p-first-last">In order to investigate the
importance of the <em>N</em>-dealkylation reaction as a function of
the total metabolism of perphenazine by HLM, the amount of
<em>N</em>-dealkylated perphenazine formed was compared with the
decrease in the substrate concentration after an incubation period
of 10 min. The initial substrate concentration was 4 μ<span class=
"small-caps">m</span>, and 200 μg protein of the H161Pool per assay
was used. The mean substrate concentration decreased by 1.010 ±
0.322 μ<span class="small-caps">m</span> (s.d.; <em>n</em> = 12),
and the mean amount of <em>N</em>-dealkylated perphenazine formed
was 0.577±0.062 μ<span class="small-caps">m</span>. Thus, the
<em>N</em>-dealkylation pathway represented 57% of the total
perphenazine metabolism catalysed by microsomes from the H161Pool
microsomes.</p>
</div>
</div>
<div id="__sec17" class="tsec sec">
<h2 class="head no_bottom_margin" id="__sec17title">Discussion</h2>
<p id="__p30" class="p p-first">Our studies using recombinant
enzymes suggest that CYPs 1A2, 3A4, 2C19 and 2D6 can catalyse the
<em>N</em>-dealkylation of perphenazine. Further work in HLM using
selective inhibitors of individual CYPs show that most of the
metabolite formation could be ascribed to the sum of the activities
of these four isoforms. This interpretation of the results is based
on the assumption that the inhibition patterns observed for the
cDNA-expressed isoforms are also valid for these in HLM. The
individual contributions of the four isoforms to
<em>N</em>-dealkylated perphenazine formation may vary with the
perphenazine concentration. The relatively high affinities and high
capacities of CYP1A2 and CYP2D6 may result in higher relative
contributions to total <em>N</em>-dealkylation by these two
isoforms at lower substrate concentrations. The clinically relevant
concentration range of perphenazine in human liver tissue is
unknown, but <em>post mortem</em> analyses of perphenazine
concentrations in humans, who had ingested an overdose of
perphenazine, showed liver concentrations of the drug that were up
to 50 times higher than those in blood [<a href="#b28" rid="b28"
class=" bibr popnode">28</a>, <a href="#b29" rid="b29" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_137064738">29</a>]. At steady-state, the usual trough plasma
perphenazine concentration is in the range 2–6 n<span class=
"small-caps">m</span>, increasing to about 20 n<span class=
"small-caps">m</span> during the drug absorption phase [<a href=
"#b5" rid="b5" class=" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_137064714">5</a>, <a href="#b7" rid="b7" class=
" bibr popnode tag_hotlink tag_tooltip" id="__tag_137064713">7</a>,
<a href="#b28" rid="b28" class=" bibr popnode">28</a>–<a href=
"#b30" rid="b30" class=" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_137064722">30</a>]. Thus, clinically relevant hepatic
concentrations are probably in the low micromolar range. The value
of 4 μ<span class="small-caps">m</span> was chosen as a compromise
between the use of a relatively low perphenazine concentration and
the achievement of a high analytical precision.</p>
<p id="__p31">Chemical inhibitors may be more or less specific for
their target CYP isoform depending among other factors on the
concentration used (21–23). We thus evaluated the minimum required
concentration for attaining a reasonably high inhibition of the
target form in relation to <em>N</em>-dealkylation of perphenazine
and the associated specificity of inhibition. Given a competitive
pattern of inhibition, relatively high inhibitor concentrations are
necessary to displace a substrate with a high affinity. Quinidine
inhibition of <em>N</em>-dealkylation of perphenazine by CYP2D6
exemplifies this situation. Perphenazine is known to have a high
affinity for CYP2D6 giving rise to important kinetic drug
interactions, and accordingly the <em>K<sub>m</sub></em> value
recorded here for the CYP2D6 mediated <em>N</em>-dealkylation was
low (1.9 μ<span class="small-caps">m</span>) [<a href="#b12" rid=
"b12" class=" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_137064719">12</a>, <a href="#b13" rid="b13" class=
" bibr popnode tag_hotlink tag_tooltip" id="__tag_137064721">13</a>
<a href="#b31" rid="b31" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_137064715">31</a>]. A relatively high quinidine
concentration (5 μ<span class="small-caps">m</span>) was necessary
to achieve an inhibition of more than 80%. This is a quinidine
concentration somewhat higher than that used by others. For
example, inhibition of 1'-hydroxylation of bufuralol can be
accomplished by concentrations below 1 μ<span class=
"small-caps">m</span> [<a href="#b32" rid="b32" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_137064727">32</a>]. Similarly, perphenazine exhibits a high
affinity to CYP1A2 <em>(K<sub>m</sub></em> 0.87 μ<span class=
"small-caps">m</span>), and it was necessary to apply a relatively
high concentration of furafylline to achieve an acceptable degree
of inhibition. Furafylline may be used either as a competitive
inhibitor without preincubation or as a mechanism-based inhibitor
requiring preincubation [<a href="#b23" rid="b23" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_137064726">23</a>]. We used furafylline as a competitive
inhibitor, because this approach is compatible with the supplier's
recommended procedure of starting the reaction by addition of
recombinant enzyme. Further, our preliminary investigations
indicated that in agreement with other studies furafylline
preincubation may lead to activation of CYP3A4 [<a href="#b33" rid=
"b33" class=" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_137064716">33</a>].</p>
<p id="__p32">The mean steady-state plasma concentration/dose (C/D)
ratio of patients lacking CYP2D6 (poor metabolizers) is about twice
that of extensive metabolizers, and based on a population kinetic
study the use of CYP2D6 genotype has been suggested for optimizing
the dose of perphenazine in patients [<a href="#b34" rid="b34"
class=" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_137064731">34</a>]. Our <em>in vitro</em> findings indicate
that on average CYP2D6 is only responsible for about 25% of the
<em>N</em>-dealkylated perphenazine formation in the liver, but the
contribution of this isoform may vary considerably from subject to
subject because of quantitative variation in liver CYP2D6 content
and the genetic polymorphism of CYP2D6. The relative abundance and
catalytic activity of CYPs 1A2, 3A4 and 2C19, involved in the
<em>N</em>-dealkylation of perphenazine, also displays large
inter-individual variation [<a href="#b35" rid="b35" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_137064732">35</a>].</p>
<p id="__p33" class="p p-last">The involvement of four isoforms in
the <em>N</em>-dealkylated perphenazine formation may help to
explain the large interindividual variation of the perphenazine C/D
observed in patients treated with the drug. However, the modest
role of CYP2D6 found in the present study does not explain that
poor metabolizers have an average C/D-value at steady-state twice
that of extensive metabolizers [<a href="#b16" rid="b16" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_137064725">16</a>]. By measurement of substrate
disappearance, we found that <em>N</em>-dealkylation amounted to
only 57% of total perphenazine metabolism mediated by our pooled
HLM preparation. Thus, it is likely that the other metabolic routes
like sulphoxidation and ring-hydroxyla-tion depend more strongly on
CYP2D6.</p>
</div>
<div id="__ackid788122" class="tsec sec">
<h2 class="head no_bottom_margin" id="__ackid788122title">
Acknowledgments</h2>
<div class="sec">
<p id="__p34">We thank Pia Ploughmann and Birgit Poulsen for
excellent technical assistance. Financial support was obtained
from: The Psychiatric Research Foundation, K &amp; V Petersen's
Foundation, The Lundbeck Foundation, The Foundation for Medical
Research, The Novo Nordic Foundation, Marshall's Foundation, The
Foundation of 1870.</p>
</div>
</div>
<div id="__ref-listid788131" class="tsec sec">
<h2 class="head no_bottom_margin" id="__ref-listid788131title">
References</h2>
<div class="ref-list-sec sec" id="reference-list">
<div class="ref-cit-blk half_rhythm" id="b1">1. <span class=
"citation">Gaertner HJ, Breyer U, Liomin G. Metabolism of
trifluoperazine, fluphenazine, prochlorperazine and perphenazine in
rats: in vitro and urinary metabolites. <span><span class=
"ref-journal">Biochem Pharmacol.</span> 1974;<span class=
"ref-vol">23</span>:303–311.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/4813347" target="pmc_ext"
ref="reftype=pubmed&amp;article-id=2015011&amp;issue-id=151583&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b2">2. <span class=
"citation">Gaertner HJ, Liomin G, Villumsen D, Bertele R, Breyer U.
Tissue metabolites of trifluorperazine, fluphenazine,
prochlorperazine, and perphenazine. Kinetics in chronic treatment.
<span><span class="ref-journal">Drug Metab Dispos.</span>
1975;<span class="ref-vol">3</span>:437–444.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/1218" target="pmc_ext" ref=
"reftype=pubmed&amp;article-id=2015011&amp;issue-id=151583&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b3">3. <span class=
"citation">Li Huang C, Kurland AA. Perphenazine (Trilafon)
metabolism in psychotic patients. <span><span class=
"ref-journal">Arch Gen Psychiatry.</span> 1963;<span class=
"ref-vol">10</span>:639–646.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/14159263" target="pmc_ext"
ref=
"reftype=pubmed&amp;article-id=2015011&amp;issue-id=151583&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b4">4. <span class=
"citation">van Kempen GMJ. Urinary excretion of perphenazine and
Its sulfoxide during administration in oral and long-acting
injectable form. <span><span class=
"ref-journal">Psychopharmacologia (Bed)</span> 1971;<span class=
"ref-vol">21</span>:283–286.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/5095416" target="pmc_ext"
ref="reftype=pubmed&amp;article-id=2015011&amp;issue-id=151583&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b5">5. <span class=
"citation">Hansen LB, Larsen NE, Vestergard P. Plasma levels of
perphenazine (Trilafon) related to development of extrapyramidal
side effects. <span><span class="ref-journal">Psychopharmacology
(Berl)</span> 1981;<span class="ref-vol">74</span>:306–309.</span>
<span class="nowrap ref pubmed">[<a href="/pubmed/6794071" target=
"pmc_ext" ref=
"reftype=pubmed&amp;article-id=2015011&amp;issue-id=151583&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b6">6. <span class=
"citation">Dahl SG. Plasma level monitoring of antipsychotic drugs.
Clinical utility. <span><span class="ref-journal">Clin
Pharmacokin.</span> 1986;<span class=
"ref-vol">11</span>:36–61.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/2868820" target="pmc_ext"
ref="reftype=pubmed&amp;article-id=2015011&amp;issue-id=151583&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b7">7. <span class=
"citation">Omerov M, Wistedt B, Bolvig-Hansen L, Larsen NE. The
relationship between perphenazine plasma levels and clinical
response in acute schizophrenia. <span><span class=
"ref-journal">Prog Neuropsychopharmacol Biol Psychiatry.</span>
1989;<span class="ref-vol">13</span>:159–166.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/2664884" target="pmc_ext"
ref="reftype=pubmed&amp;article-id=2015011&amp;issue-id=151583&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b8">8. <span class=
"citation">Joergensen A. Metabolism and pharmacokinetics of
antipsychotic drugs. <span><span class="ref-journal">Prog Drug
Metabolism.</span> 1986;<span class=
"ref-vol">9</span>:111–174.</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b9">9. <span class=
"citation">Hals PA, Hall H, Dahl SG. Phenothiazine drug
metabolites: dopamine D2 receptor, alpha 1- and alpha
2-adrenoceptor binding. <span><span class="ref-journal">Eur J
Pharmacol.</span> 1986;<span class=
"ref-vol">125</span>:373–381.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/2874041" target="pmc_ext"
ref="reftype=pubmed&amp;article-id=2015011&amp;issue-id=151583&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b10">10. <span class=
"citation">Hansen LB, Elley J, Christensen TR, Larsen NE, Naestoft
J, Hvidberg EF. Plasma levels of perphenazine and its major
metabolites during simultaneous treatment with anticholinergic
drugs. <span><span class="ref-journal">BrJ Clin Pharmacol.</span>
1979;<span class="ref-vol">7</span>:75–80.</span> <span class=
"nowrap ref pmc">[<a class="int-reflink" href=
"/pmc/articles/PMC1429600/">PMC free article</a>]</span>
<span class="nowrap ref pubmed">[<a href="/pubmed/760745" target=
"pmc_ext" ref=
"reftype=pubmed&amp;article-id=2015011&amp;issue-id=151583&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b11">11. <span class=
"citation">Venkatakrishnan K, von Moltke LL, Greenblatt DJ.
Nortriptyline E-1 0-hydroxylation <em>in vitro</em> is mediated by
human CYP2D6 (high affinity) and CYP3A4 (low affinity):
implications for interactions with enzyme-inducing drugs.
<span><span class="ref-journal">J Clin Pharmacol.</span>
1999;<span class="ref-vol">39</span>:567–577.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/10354960" target="pmc_ext"
ref=
"reftype=pubmed&amp;article-id=2015011&amp;issue-id=151583&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b12">12. <span class=
"citation">Kragh-Sorensen P, Borga O, Garle M, et al. Effect of
simultaneous treatment with low doses of perphenazine on plasma and
urine concentrations of nortriptyline and 10— hydroxynortriptyline.
<span><span class="ref-journal">EurJ Clin Pharmacol.</span>
1977;<span class="ref-vol">11</span>:479–483.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/891595" target="pmc_ext" ref=
"reftype=pubmed&amp;article-id=2015011&amp;issue-id=151583&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b13">13. <span class=
"citation">Mulsant BH, Foglia JP, Sweet RA, Rosen J, Lo KH, Pollock
BG. The effects of perphenazine on the concentration of
nortriptyline and its hydroxymetabolites in older patients.
<span><span class="ref-journal">J Clin Psychopharmacol.</span>
1997;<span class="ref-vol">17</span>:318–321.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/9241013" target="pmc_ext"
ref="reftype=pubmed&amp;article-id=2015011&amp;issue-id=151583&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b14">14. <span class=
"citation">Ozdemir V, Naranjo CA, Herrmann N, Reed K, Sellers EM,
Kalow W. Paroxetine potentiates the central nervous system side
effects of perphenazine: contribution of cytochrome P4502D6
inhibition in vivo. <span><span class="ref-journal">Clin Pharmacol
Ther.</span> 1997;<span class="ref-vol">62</span>:334–347.</span>
<span class="nowrap ref pubmed">[<a href="/pubmed/9333110" target=
"pmc_ext" ref=
"reftype=pubmed&amp;article-id=2015011&amp;issue-id=151583&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b15">15. <span class=
"citation">Dahl-Puustinen ML, Liden A, Alm C, Nordin C, Bertilsson
L. Disposition of perphenazine is related to polymorphic
debrisoquin hydroxylation in human beings. <span><span class=
"ref-journal">Clin Pharmacol Ther.</span> 1989;<span class=
"ref-vol">46</span>:78–81.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/2743709" target="pmc_ext"
ref="reftype=pubmed&amp;article-id=2015011&amp;issue-id=151583&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b16">16. <span class=
"citation">Linnet K, Wiborg O. Steady-state serum concentrations of
the neuroleptic perphenazine in relation to CYP2D6 genetic
polymorphism. <span><span class="ref-journal">Clin Pharmacol
Ther.</span> 1996;<span class="ref-vol">60</span>:41–47.</span>
<span class="nowrap ref pubmed">[<a href="/pubmed/8689810" target=
"pmc_ext" ref=
"reftype=pubmed&amp;article-id=2015011&amp;issue-id=151583&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b17">17. <span class=
"citation">Linnet K, Olesen OV. Metabolism of clozapine by
cDNA-expressed human cytochrome P450 enzymes. <span><span class=
"ref-journal">Drug Metab Dispos.</span> 1997;<span class=
"ref-vol">25</span>:1379–1382.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/9394027" target="pmc_ext"
ref="reftype=pubmed&amp;article-id=2015011&amp;issue-id=151583&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b18">18. <span class=
"citation">Sesardic D, Boobis AR, Murray BP, et al. Furafylline is
a potent and selective inhibitor of cytochrome P450IA2 in man.
<span><span class="ref-journal">Br J Clin Pharmacol.</span>
1990;<span class="ref-vol">29</span>:651–663.</span> <span class=
"nowrap ref pmc">[<a class="int-reflink" href=
"/pmc/articles/PMC1380167/">PMC free article</a>]</span>
<span class="nowrap ref pubmed">[<a href="/pubmed/2378786" target=
"pmc_ext" ref=
"reftype=pubmed&amp;article-id=2015011&amp;issue-id=151583&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b19">19. <span class=
"citation">Rasmussen BB, Nielsen TL, Brosen K. Fluvoxamine inhibits
the CYP2C19-catalysed metabolism of proguanil in vitro.
<span><span class="ref-journal">Eur J Clin Pharmacol.</span>
1998;<span class="ref-vol">54</span>:735–740.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/9923577" target="pmc_ext"
ref="reftype=pubmed&amp;article-id=2015011&amp;issue-id=151583&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b20">20. <span class=
"citation">Baldwin SJ, Bloomer JC, Smith GJ, Ayrton AD, Clarke SE,
Cheney RJ. Ketoconazole and sulphaphenazole as the respective
selective inhibitors of P4503A and 2C9. <span><span class=
"ref-journal">Xenobiotica.</span> 1995;<span class=
"ref-vol">25</span>:261–270.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/7618352" target="pmc_ext"
ref="reftype=pubmed&amp;article-id=2015011&amp;issue-id=151583&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b21">21. <span class=
"citation">Eagling VA, Tjia JF, Back DJ. Differential selectivity
of cytochrome P450 inhibitors against probe substrates in human and
rat liver microsomes. <span><span class="ref-journal">Br J Clin
Pharmacol.</span> 1998;<span class=
"ref-vol">45</span>:107–114.</span> <span class=
"nowrap ref pmc">[<a class="int-reflink" href=
"/pmc/articles/PMC1873357/">PMC free article</a>]</span>
<span class="nowrap ref pubmed">[<a href="/pubmed/9491822" target=
"pmc_ext" ref=
"reftype=pubmed&amp;article-id=2015011&amp;issue-id=151583&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b22">22. <span class=
"citation">Newton DJ, Wang RW, Lu AYH. Cytochrome P450 inhibitors.
Evaluation of specificities in the in vitro metabolism of
therapeutic agents by human liver microsomes. <span><span class=
"ref-journal">Drug Metab Dispos.</span> 1995;<span class=
"ref-vol">23</span>:154–158.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/7720520" target="pmc_ext"
ref="reftype=pubmed&amp;article-id=2015011&amp;issue-id=151583&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b23">23. <span class=
"citation">Bourrie M, Meunier V, Berger Y, Fabre G. Cytochrome P450
isoform inhibitors as a tool for the investigation of metabolic
reactions catalyzed by human liver microsomes. <span><span class=
"ref-journal">J Pharmacol Exp Ther.</span> 1996;<span class=
"ref-vol">277</span>:321–332.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/8613937" target="pmc_ext"
ref="reftype=pubmed&amp;article-id=2015011&amp;issue-id=151583&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b24">24. <span class=
"citation">Segel IH. <span class="ref-journal">Enzyme
kinetics.</span> New York: John Wiley &amp; Sons, Inc.; 1993. p.
105.</span></div>
<div class="ref-cit-blk half_rhythm" id="b25">25. <span class=
"citation">Olesen OV, Linnet K. Studies of the stereoselective
metabolism of citalopram by human liver microsomes and
cDNA-expressed cytochrome P450 enzymes. <span><span class=
"ref-journal">Pharmacology.</span> 1999;<span class=
"ref-vol">59</span>:298–309.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/10575324" target="pmc_ext"
ref=
"reftype=pubmed&amp;article-id=2015011&amp;issue-id=151583&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b26">26. <span class=
"citation">Hofstee BHJ. On the evaluation of the constants
V<sub>m</sub> and K<sub>m</sub> in enzyme reactions.
<span><span class="ref-journal">Science.</span> 1952;<span class=
"ref-vol">116</span>:329–331.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/12984118" target="pmc_ext"
ref=
"reftype=pubmed&amp;article-id=2015011&amp;issue-id=151583&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b27">27. <span class=
"citation">Venkatakrishnan K, von Moltke LL, Greenblatt DJ.
Relative quantities of catalytically active CYP2C9 and 2C19 in
human liver microsomes: application of the relative activity factor
approach. <span><span class="ref-journal">J Pharm Sci.</span>
1998;<span class="ref-vol">87</span>:845–853.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/9649353" target="pmc_ext"
ref="reftype=pubmed&amp;article-id=2015011&amp;issue-id=151583&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b28">28. <span class=
"citation">Baselt RC, Cravey RH. <span class=
"ref-journal">Disposition of toxic drugs and chemicals in man,
4.</span> Foster City, Ca: Chemical Toxicology Institute; 1995. pp.
598–600.</span></div>
<div class="ref-cit-blk half_rhythm" id="b29">29. <span class=
"citation">Levine B, Jenkins A, Chute D, Smialek JE. Perphenazine
distribution in a postmortem case. <span><span class=
"ref-journal">J Anal Toxicol.</span> 1999;<span class=
"ref-vol">23</span>:127–129.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/10192418" target="pmc_ext"
ref=
"reftype=pubmed&amp;article-id=2015011&amp;issue-id=151583&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b30">30. <span class=
"citation">Eggert Hansen C, Rosted Christensen T, Elley J, et al.
Clinical pharmacokinetic studies of perphenazine.
<span><span class="ref-journal">Br J Clin Pharmacol.</span>
1976;<span class="ref-vol">3</span>:915–923.</span> <span class=
"nowrap ref pmc">[<a class="int-reflink" href=
"/pmc/articles/PMC1428936/">PMC free article</a>]</span>
<span class="nowrap ref pubmed">[<a href="/pubmed/973987" target=
"pmc_ext" ref=
"reftype=pubmed&amp;article-id=2015011&amp;issue-id=151583&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b31">31. <span class=
"citation">Shin J-G, Soukhova N, Flockhart DA. Effect of
antipsychotic drugs on human liver cytochrome P-450 (CYP) isoforms
in vitro: Preferential inhibition of CYP2D6. <span><span class=
"ref-journal">Drug Metab Dispos.</span> 1999;<span class=
"ref-vol">27</span>:1078–1084.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/10460810" target="pmc_ext"
ref=
"reftype=pubmed&amp;article-id=2015011&amp;issue-id=151583&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b32">32. <span class=
"citation">Speirs CJ, Murray S, Boobis AR, Seddon CE, Davies DS.
Quinidine and the identification of drugs whose elimination is
impaired in subjects classified as poor metabolizers of
debrisoquine. <span><span class="ref-journal">BrJ Clin
Pharmacol.</span> 1986;<span class=
"ref-vol">22</span>:739–743.</span> <span class=
"nowrap ref pmc">[<a class="int-reflink" href=
"/pmc/articles/PMC1401220/">PMC free article</a>]</span>
<span class="nowrap ref pubmed">[<a href="/pubmed/3567021" target=
"pmc_ext" ref=
"reftype=pubmed&amp;article-id=2015011&amp;issue-id=151583&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b33">33. <span class=
"citation">Sai Y, Dai R, Yang TJ, et al. Assessment of specificity
of eight chemical inhibitors using cDNA-expressed cytochromes P450.
<span><span class="ref-journal">Xenobiotica.</span>
2000;<span class="ref-vol">30</span>:327–343.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/10821163" target="pmc_ext"
ref=
"reftype=pubmed&amp;article-id=2015011&amp;issue-id=151583&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b34">34. <span class=
"citation">Jerling M, Dahl ML, Aberg-Wistedt A, et al. The CYP2D6
genotype predicts the oral clearance of the neuroleptic agents
perphenazine and zuclopenthixol. <span><span class=
"ref-journal">Clin Pharmacol Ther.</span> 1996;<span class=
"ref-vol">59</span>:423–428.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/8612387" target="pmc_ext"
ref="reftype=pubmed&amp;article-id=2015011&amp;issue-id=151583&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b35">35. <span class=
"citation">Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP.
Interindividual variations in human liver cytochrome P-450 enzymes
involved in the oxidation of drugs, carcinogens and toxic
chemicals: studies with liver microsomes of 30 Japanese and
Caucasians. <span><span class="ref-journal">J Pharmacol Exp
Ther.</span> 1994;<span class="ref-vol">270</span>:414–423.</span>
<span class="nowrap ref pubmed">[<a href="/pubmed/8035341" target=
"pmc_ext" ref=
"reftype=pubmed&amp;article-id=2015011&amp;issue-id=151583&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
</div>
</div>
</div>
<!--post-content-->
<hr class="whole_rhythm no_bottom_margin" />
<div class="courtesy-note no_margin small">Articles from
<span class="acknowledgment-journal-title">British Journal of
Clinical Pharmacology</span> are provided here courtesy of
<strong>British Pharmacological Society</strong></div>
</div>
</div>
<!-- Book content --></div>
<div id="rightcolumn" class="four_col col last">
<!-- Custom content above discovery portlets -->
<div class="col6"></div>
<div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi=
"http://www.w3.org/2001/XMLSchema-instance">
<div class="try-button"><a href=
"/pmc/articles/PMC2015011/?report=reader"><img src=
"//static.pubmed.gov/portal/portal3rc.fcgi/4072591/img/3838809"
alt="PubReader format: click here to try" /></a></div>
<div class="format-menu">
<h2>Formats:</h2>
<ul>
<li class="selected">Article</li>
<li style="list-style: none">|</li>
<li><a href=
"/pmc/articles/PMC2015011/?report=reader">PubReader</a></li>
<li style="list-style: none">|</li>
<li class="epub-link"><a href="/pmc/articles/PMC2015011/epub/">ePub
(beta)</a></li>
<li style="list-style: none">|</li>
<li><a href="/pmc/articles/PMC2015011/pdf/bcp0050-0563.pdf">PDF
(145K)</a></li>
<li style="list-style: none">|</li>
<li><a href="#" data-citationid="PMC2015011" class=
"citationexporter ctxp">Citation</a></li>
</ul>
</div>
</div>
<div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi=
"http://www.w3.org/2001/XMLSchema-instance" class="share-buttons">
<h2>Share</h2>
<ul>
<li class="facebook"><a href=
"https://www.facebook.com/sharer/sharer.php?u=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2015011%2F">
<img src=
"//static.pubmed.gov/portal/portal3rc.fcgi/4072591/img/4047626"
alt="Share on Facebook" /> Facebook</a></li>
<li class="twitter"><a href=
"https://twitter.com/intent/tweet?url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2015011%2F&amp;text=Identification%20of%20the%20human%20cytochrome%20P450%20isoforms%20mediating%20in%20vitro%20N-dealkylation%20of%20perphenazine">
<img src=
"//static.pubmed.gov/portal/portal3rc.fcgi/4072591/img/4047627"
alt="Share on Twitter" /> Twitter</a></li>
<li class="gplus"><a href=
"https://plus.google.com/share?url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2015011%2F">
<img src=
"//static.pubmed.gov/portal/portal3rc.fcgi/4072591/img/4047628"
alt="Share on Google Plus" /> Google+</a></li>
</ul>
</div>
<div id="ajax-portlets" data-pmid="11136295" data-aiid="2015011"
data-aid="2015011" data-iid="151583" data-domainid="279"
data-domain="brjclinpharm" data-accid="PMC2015011" data-md5=
"2fff75b89aeb209d47f76a104d90913e"></div>
<!-- Custom content below discovery portlets -->
<div class="col7"></div>
</div>
</div>
<!-- Custom content after all -->
<div class="col8"></div>
<div class="col9"></div>
<script src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js">
</script> <script>
<![CDATA[
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
]]>
</script>
<div id="body-link-poppers"></div>
</div>
<div class="bottom">
<div id="NCBIFooter_dynamic">
<div class="breadcrumbs">You are here: <span id=
"breadcrumb_text"><a href="/guide/">NCBI</a> &gt; <a href=
"http://www.ncbi.nlm.nih.gov/guide/literature/">Literature</a> &gt;
<a href="http://www.ncbi.nlm.nih.gov/pmc/">PubMed Central
(PMC)</a></span></div>
<a id="help-desk-link" class="help_desk jig-ncbihelpwindow" target=
"_blank" href=
"/sites/ehelp?&amp;Ncbi_App=pmc&amp;Db=pmc&amp;Page=literature&amp;Snapshot=/projects/PMC/PMCViewer@4.35&amp;Time=2016-04-01T09:54:11-04:00&amp;Host=ptpmc202">Write
to the Help Desk</a></div>
<div class="footer" id="footer">
<div class="subfooter"></div>
<script type="text/javascript" src=
"/portal/portal3rc.fcgi/static/js/preloaderWidget.js">
</script>
<div id="external-disclaimer" class="offscreen_noflow">External
link. Please review our <a href=
"http://www.nlm.nih.gov/privacy.html">privacy policy</a>.</div>
<div id="ncbifooter" class="contact_info">
<div id="footer-contents-right">
<div id="nlm_thumb_logo"><a href="http://www.nlm.nih.gov" title=
"NLM">NLM</a></div>
<div id="nih_thumb_logo"><a href="http://www.nih.gov" title=
"NIH">NIH</a></div>
<div id="hhs_thumb_logo"><a href="http://www.dhhs.gov" title=
"DHHS">DHHS</a></div>
<div id="usagov_thumb_logo"><a href="http://www.usa.gov" title=
"USA.gov">USA.gov</a></div>
</div>
<div id="footer-contents-left"><a href=
"/About/disclaimer.html">Copyright</a> | <a href=
"/About/disclaimer.html#disclaimer">Disclaimer</a> | <a href=
"http://www.nlm.nih.gov/privacy.html" class="newdomain">Privacy</a>
| <a href="/guide/browsers/">Browsers</a> | <a href=
"http://www.nlm.nih.gov/accessibility.html">Accessibility</a> |
<a href="/About/glance/contact_info.html">Contact</a>
<p class="address vcard"><span class="url"><a class=
"fn url newdomain" href="http://www.ncbi.nlm.nih.gov">National
Center for Biotechnology Information</a>,</span> <span class=
"org url"><a href="http://www.nlm.nih.gov/">U.S. National Library
of Medicine</a></span> <span class="adr"><span class=
"street-address">8600 Rockville Pike</span>, <span class=
"locality">Bethesda</span> <span class="region">MD</span>,
<span class="postal-code">20894</span> <span class=
"country-name">USA</span></span></p>
</div>
</div>
<script type="text/javascript" src=
"/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1">
</script> <script type="text/javascript" src=
"/portal/portal3rc.fcgi/static/js/hfjs2.js">
</script></div>
</div>
</div>
<!--/.page--></div>
<!--/.wrap--></div>
<!-- /.twelve_col --></div>
<!-- /.grid -->
 <!-- BESelector tab -->
 <noscript><img alt="statistics" src=
"/stat?jsdisabled=true&amp;ncbi_db=pmc&amp;ncbi_pdid=article&amp;ncbi_acc=&amp;ncbi_domain=brjclinpharm&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/articles/PMC2015011/&amp;ncbi_app=pmc" />
</noscript> <!-- usually for JS scripts at page bottom -->
 <!--<component id="PageFixtures" label="styles"></component>-->
 
<!-- F4FC46756FE7D821_0200SID /projects/PMC/PMCViewer@4.35 ptpmc202 v4.1.r480124 Mon, Sep 28 2015 02:46:19 -->
 <script type="text/javascript" src=
"//static.pubmed.gov/portal/portal3rc.fcgi/4072591/js/3879255/3728312/3818874/3821238/4064716/4072593/4064449/3921943/4070217/4065628.js"
snapshot="pmc">
</script>
</body>
</html>
